Non-Hodgkin's lymphoma, CLL, rheumatoid arthritis, granulomatosis with polyangiitis, microscopic polyangiitis
Haematology · 2018–2018
1decision
1medicine
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| rituximab Biosimilar rituximab for all indications for which the reference brand MabThera is currently PBS listed: Non-Hodgkin's lymphoma, chronic lymphocytic leukaemia,… | Mar 2018 | Recommended | input received Lymphoma Australia |
Who spoke
Lymphoma Australia
What the PBS pays
$24M in government benefit over 2024–25, across 57,210 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| rituximab | $23.9M |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.